NASDAQ · NIVFW
NewGenIvf Group Limited Warrants financials
$0.01930.00%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $4.7M | $5.4M |
| Gross profit | $955.8K | $1.8M |
| Gross margin | 20.2% | 33.6% |
| Operating income | -$10.7M | -$1.2M |
| Net income | $9.9M | -$524.6K |
| Net margin | 209.0% | −9.7% |
| Diluted EPS | $27.36 | $-39678.84 |
| EBITDA | -$10.5M | -$1.1M |
| Operating cash flow | -$10.9M | -$8.3M |
| Free cash flow | -$11.1M | -$8.3M |
| Diluted shares | 0.4M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $758.6K | $457.7K |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $4.4M | $2.4M |
| Total assets | $32.7M | $3.6M |
| Total liabilities | $6.7M | $5.1M |
| Shareholders' equity | $26.0M | -$1.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology